Skip to main content
Delfa

← All assets

Neflamapimod

8 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

8

Ongoing

1

Recruiting

0

Completed

7

Sites

111

Countries

6

Endpoints

119

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 119 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
8

Trials by status

Active, not recruiting
1
Completed
7

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Fluid / digital biomarkers
35
Global cognition
18
Memory
14
Executive function / language
9
Other (unclassified)
9
Amyloid biomarkers
8
Safety / tolerability / PK
7
Neurodegeneration biomarkers
5
Other clinical outcomes
5
Behavior / neuropsychiatric
4
Tau biomarkers
3
Neuroimaging
1
Caregiver / quality of life
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 20 of 119 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

8

Mini-Mental State Examination (MMSE)Cognition

4

Phosphorylated tau 181 (p-tau181)Fluid/digital

2

Neurofilament light (NfL)Neurodeg.

2

Phosphorylated tau 181 (p-tau181)Amyloid

2

Neuropsychiatric Inventory (NPI)Behavior

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

8 of 8

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT05869669RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Neflamapimod

Lewy body dementia

Dementia with Lewy bodiesPh 2Completed40May 2025-
REVERSE-SDProof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

Neflamapimod

Alzheimer’s disease

Tau biomarker required (CSF)Ph 2Completed38Jun 20192results
AscenD-LBCognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

Neflamapimod

Lewy body dementia

Dementia with Lewy bodiesPh 2Completed24Jun 20202results
NCT07033481Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

Neflamapimod

Frontotemporal dementia

CDR global 0.5Ph 2Active, not recruiting7Sep 2026-
NCT06815965A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Neflamapimod

Lewy body dementia

Dementia with Lewy bodiesPh 2Completed2Mar 2026-
NCT02423200Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Neflamapimod

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MCI due to ADPh 2Completed1Sep 20161results
VIPEffect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients

Neflamapimod

Alzheimer’s disease

MMSE ≥20Ph 2Completed1Apr 20212
NCT02423122A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

Neflamapimod

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Alzheimer's diseasePh 2Completed1Jul 20161results

Showing 1-8 of 8 trials